| DIRECT COMPETITOR COMPARISON | |
| GERN | Pvt1 | STEM | Pvt2 | Industry | | Market Cap: | 488.37M | N/A | 126.63M | N/A | 163.44M | | Employees: | 159 | 3,6201 | 55 | N/A | 95 | | Qtrly Rev Growth (yoy): | 34.60% | N/A | 1,945.10% | N/A | 20.50% | | Revenue (ttm): | 1.66M | 400.60M1 | 747.39K | N/A | 46.74M | | Gross Margin (ttm): | N/A | N/A | 73.11% | N/A | 68.58% | | EBITDA (ttm): | -67.81M | N/A | -25.17M | N/A | -7.12M | | Oper Margins (ttm): | -4,178.08% | N/A | -3,569.49% | N/A | 2.25% | | Net Income (ttm): | -69.61M | N/A | -31.88M | N/A | N/A | | EPS (ttm): | -0.816 | N/A | -0.321 | N/A | -0.17 | | P/E (ttm): | N/A | N/A | N/A | N/A | 18.38 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.04 | | P/S (ttm): | 300.47 | N/A | 172.60 | N/A | 4.37 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.50 | -1.02% | 57.19B | 12.32 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 46.92 | -1.12% | 13.57B | 15.70 | | Genzyme Corp. | GENZ | 51.07 | -0.87% | 13.55B | 29.12 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.56 | -0.89% | 41.90B | 18.00 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 49.95 | -1.85% | 8.91B | 1019.39 | | Teva Pharmaceutical Industries Limited | TEVA | 52.88 | -0.53% | 46.59B | 48.38 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 36.96 | -2.25% | 3.92B | 19.05 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 11.95 | -1.08% | 2.97B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.01 | -1.53% | 5.50B | 110.49 | | Pfizer Inc. | PFE | 18.25 | -1.83% | 147.27B | 15.16 | | Johnson & Johnson | JNJ | 62.89 | -0.65% | 173.52B | 13.73 | | GlaxoSmithKline plc | GSK | 42.26 | -1.45% | 107.13B | 13.21 | | Sanofi-Aventis | SNY | 38.43 | -2.61% | 100.35B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.38 | -0.84% | 125.78B | 16.58 | | RHHBY.PK | 41.46 | -1.96% | N/A | N/A | | AstraZeneca plc | AZN | 45.29 | -2.35% | 65.67B | 9.09 | | Abbott Laboratories | ABT | 54.08 | -0.61% | 83.65B | 14.65 | | Bristol-Myers Squibb Co. | BMY | 25.38 | -1.05% | 50.28B | 13.13 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | STEM | | StemCells, Inc. CEO Martin McGlynn Featured On BioBusiness.TV's "Stem Cell Review" Series
Mon, Nov 23 -
Business Wire | | • | STEM | | StemCells, Inc. Initiates Landmark Trial Targeting "Communication Highway" of the Brain
Mon, Nov 23 -
Business Wire | | • | STEM | | STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Fri, Nov 20 -
EDGAR Online | | • | STEM | | StemCells, Inc. Provides Update on NCL Program Meeting with FDA
Wed, Nov 18 -
Business Wire | | • | STEM | | Trading Outlook for StemCells Inc. Issued by InvestorSoup.com
Thu, Nov 12 -
GlobeNewswire | | | All Headlines for these symbols... |
|
|
|
1.48% Nasdaq 
Competitors
